Study Details
Design, interventions, and primary outcomes
About This Study
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
Design
Interventions / Regimen
- Drug: ETX-19477 — Oral medication taken daily
Primary Outcomes
- To characterize the safety and tolerability of ETX-19477, the maximum tolerated dose (MTD) and/or RP2D of ETX-19477 (6 months)
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2024-05-13
Completion: 2026-12
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
- Daniel McCormick (STUDY_DIRECTOR) - 858 Therapeutics, Inc.
- Drug: ETX-19477 — Oral medication taken daily